BioDelivery Sciences International Stock Price, News & Analysis (NASDAQ:BDSI)

$2.83 0.03 (1.07 %)
(As of 12/13/2017 02:17 AM ET)
Previous Close$2.80
Today's Range$2.76 - $2.85
52-Week Range$1.55 - $3.60
Volume201,338 shs
Average Volume538,592 shs
Market Capitalization$156.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.74

About BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International logoBioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:BDSI
CUSIP09060J10
Phone919-582-9050

Debt

Debt-to-Equity Ratio1.89%
Current Ratio1.28%
Quick Ratio1.07%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.55 million
Price / Sales10.15
Cash FlowN/A
Price / CashN/A
Book Value($0.33) per share
Price / Book-8.56

Profitability

Trailing EPS($0.19)
Net Income$-67,130,000.00
Net Margins10.40%
Return on Equity33.83%
Return on Assets6.43%

Miscellaneous

Employees99
Outstanding Shares55,880,000

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.01. The specialty pharmaceutical company had revenue of $11.25 million for the quarter, compared to analyst estimates of $9.40 million. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. The company's quarterly revenue was up 215.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) earnings per share. View BioDelivery Sciences International's Earnings History.

Where is BioDelivery Sciences International's stock going? Where will BioDelivery Sciences International's stock price be in 2017?

6 analysts have issued 1 year price objectives for BioDelivery Sciences International's shares. Their forecasts range from $4.00 to $5.00. On average, they expect BioDelivery Sciences International's stock price to reach $4.50 in the next year. View Analyst Ratings for BioDelivery Sciences International.

What are Wall Street analysts saying about BioDelivery Sciences International stock?

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:

  • 1. According to Zacks Investment Research, "BioDelivery’s has secured improved positioning in six new managed care contracts providing preferred access to its key drug Bunavail since July last year, which is expected to boost the drug’s sales and profitability in 2017. Moreover, its second marketed drug Belbuca’s sales hit all-time high since the product was launched a year ago. However, the company recently discontinued development of clonidine topical gel for management of painful diabetic neuropathy. BioDelivery’s portfolio as well as its pipeline candidates may also face sever competition as it targets a highly genericized and crowded market. Its share significantly outperformed the Zacks classified Medical-Biomed/Genetics market so far this year. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has mixed record of earnings surprises in recent quarters." (7/17/2017)
  • 2. Cantor Fitzgerald analysts commented, "A Lot of Moving Parts and 1x Items: BDSI reported 1Q17 results posting net income of $0.89, the majority of which was attributed to positive effects of the Belbuca return. These items included $20M in deferred revenue recognition, $27M in non-cash bargain purchase gain and a $16M tax benefit. Without these additions, BDSI would have reported a loss of ($0.23). BDSI finished 1Q with $35.2M in cash, which the company estimates should fund operations into 2H18. We have adjusted our estimates to reflect quarter and year end results. Alignment of Fundamentals: We have watched the re-launch of Belbuca closely following the ENDP transition with the recently expanded sales force growing Rx numbers through 1Q and April, per Symphony data. More importantly, $/Rx continues to increase with due to larger prescriptions and incremental price increases. We also note a significant shift to commercial payor which should allow for increased gross/net adding to the top-line. The expanded sales force of 65 armed with revised marketing messaging, particularly around titration, has been targeting physicians familiar with the buprenorphine molecule with success, in our view. We believe additional education campaigns such as speaker programs and a PAINWeekEND symposium will drive interest. Additional Upside: We see additional upside as BDSI focuses on managed Medicaid contracts of which BDSI as of Feb." (5/16/2017)
  • 3. FBR & Co analysts commented, "BioDelivery reported 4Q16 results after the close on March 16. On the morning of March 17, management hosted a call to provide an update on 2017 progress. The company recently announced that it has entered into a senior credit facility with affiliates of CRG LP , which is a healthcare-focused investment firm, and currently has debt financing of up to $75M secured, with initial proceeds extending the company’s cash runway into 2H18." (3/20/2017)

Are investors shorting BioDelivery Sciences International?

BioDelivery Sciences International saw a increase in short interest in November. As of November 30th, there was short interest totalling 1,433,007 shares, an increase of 32.5% from the November 15th total of 1,081,713 shares. Based on an average daily trading volume, of 561,756 shares, the short-interest ratio is presently 2.6 days. Currently, 2.8% of the shares of the company are sold short.

Who are some of BioDelivery Sciences International's key competitors?

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the folowing people:

  • Frank E. O'Donnell Jr., M.D., Executive Chairman of the Board (Age 66)
  • Mark A. Sirgo, Vice Chairman of the Board (Age 64)
  • Ernest R. De Paolantonio CPA, Chief Financial Officer, Treasurer, Secretary (Age 63)
  • Niraj Vasisht Ph.D., Senior Vice President of Product Development and Chief Technical Officer (Age 52)
  • Peter L. Ginsberg, Vice President - Business Development
  • William B. Stone, Lead Independent Director (Age 73)
  • Timothy C. Tyson, Director (Age 62)
  • Charles J. Bramlage, Independent Director (Age 55)
  • Thomas W. D'Alonzo, Independent Director (Age 72)
  • Barry I. Feinberg M.D., Independent Director (Age 60)

Who owns BioDelivery Sciences International stock?

BioDelivery Sciences International's stock is owned by many different of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (6.92%), Ameriprise Financial Inc. (2.56%), Royce & Associates LP (2.31%), EAM Investors LLC (1.40%), GSA Capital Partners LLP (0.73%) and Krilogy Financial LLC (0.24%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Charles Bramlage, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr and William B Stone. View Institutional Ownership Trends for BioDelivery Sciences International.

Who sold BioDelivery Sciences International stock? Who is selling BioDelivery Sciences International stock?

BioDelivery Sciences International's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc. and GSA Capital Partners LLP. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht and Paolantonio Ernest Robert De. View Insider Buying and Selling for BioDelivery Sciences International.

Who bought BioDelivery Sciences International stock? Who is buying BioDelivery Sciences International stock?

BioDelivery Sciences International's stock was purchased by a variety of institutional investors in the last quarter, including Royce & Associates LP, Stonepine Capital Management LLC, EAM Investors LLC, JPMorgan Chase & Co., Krilogy Financial LLC and Wells Fargo & Company MN. Company insiders that have bought BioDelivery Sciences International stock in the last two years include Barry I Feinberg, Charles Bramlage, Niraj Vasisht and Paolantonio Ernest Robert De. View Insider Buying and Selling for BioDelivery Sciences International.

How do I buy BioDelivery Sciences International stock?

Shares of BioDelivery Sciences International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BioDelivery Sciences International stock can currently be purchased for approximately $2.83.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $156.47 million and generates $15.55 million in revenue each year. The specialty pharmaceutical company earns $-67,130,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. BioDelivery Sciences International employs 99 workers across the globe.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]


MarketBeat Community Rating for BioDelivery Sciences International (BDSI)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  440
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioDelivery Sciences International (NASDAQ:BDSI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.862.71
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.50$4.50$5.36$5.00
Price Target Upside: 91.49% upside73.08% upside78.57% upside117.39% upside

BioDelivery Sciences International (NASDAQ:BDSI) Consensus Price Target History

Price Target History for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/27/2017HC WainwrightSet Price TargetBuy$5.00HighView Rating Details
11/13/2017Roth CapitalSet Price TargetBuy$5.00N/AView Rating Details
10/22/2017Piper Jaffray CompaniesSet Price TargetBuy$4.00N/AView Rating Details
10/12/2017Cantor FitzgeraldSet Price TargetBuy$5.00N/AView Rating Details
7/24/2017Janney Montgomery ScottBoost Price TargetBuy -> Fair Value$3.00 -> $4.00HighView Rating Details
5/16/2017FBR & CoSet Price TargetBuy$4.00MediumView Rating Details
3/14/2016LaidlawLower Price TargetBuy$17.00 -> $11.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

BioDelivery Sciences International (NASDAQ:BDSI) Earnings History and Estimates Chart

Earnings by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ BDSI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.22)($0.21)$9.40 million$11.25 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.23)($0.27)$8.45 million$8.70 millionViewListenView Earnings Details
5/15/2017Q1 2017$0.09$0.58$27.07 million$29.48 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.26)($0.29)$6.37 million$3.90 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.30)$3.58 million$3.60 millionViewListenView Earnings Details
8/9/2016Q216($0.31)($0.31)$3.35 million$5.00 millionViewN/AView Earnings Details
5/10/2016Q116($0.35)($0.36)$2.96 million$3.00 millionViewListenView Earnings Details
3/10/2016Q415$0.55$0.19$52.40 million$32.20 millionViewListenView Earnings Details
11/9/2015Q315($0.34)($0.39)$1.56 million$1.20 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.37)$3.29 million$1.70 millionViewListenView Earnings Details
5/11/2015Q115($0.20)($0.16)$10.80 million$13.10 millionViewListenView Earnings Details
3/16/2015Q414($0.40)($0.51)$4.00 million$2.50 millionViewN/AView Earnings Details
11/5/2014Q3 2014($0.29)($0.39)$3.02 million$1.82 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.07)($0.14)$11.65 million$13.89 millionViewN/AView Earnings Details
5/9/2014Q114($0.15)($0.11)$11.60 million$20.69 millionViewN/AView Earnings Details
3/14/2014($0.22)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

BioDelivery Sciences International (NASDAQ:BDSI) Earnings Estimates

2017 EPS Consensus Estimate: ($0.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.22)$0.09($0.10)
Q2 20173($0.31)($0.20)($0.25)
Q3 20173($0.28)($0.23)($0.25)
Q4 20173($0.27)($0.21)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioDelivery Sciences International (NASDAQ:BDSI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

BioDelivery Sciences International (NASDAQ BDSI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.73%
Institutional Ownership Percentage: 44.18%
Insider Trades by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)
Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ BDSI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/21/2017Mark A SirgoInsiderSell201,373$2.84$571,899.32View SEC Filing  
9/20/2017Mark A SirgoCEOSell65,405$2.75$179,863.75View SEC Filing  
9/19/2017Mark A SirgoCEOSell24,516$2.75$67,419.00View SEC Filing  
9/18/2017Mark A SirgoCEOSell6,000$2.85$17,100.00View SEC Filing  
9/15/2017Mark A SirgoCEOSell54,833$2.90$159,015.70View SEC Filing  
9/14/2017Mark A SirgoCEOSell50,000$2.95$147,500.00View SEC Filing  
3/31/2017Mark A SirgoCEOSell110,895$1.90$210,700.50View SEC Filing  
3/23/2017Francis E Odonnell JrDirectorSell750$1.90$1,425.00View SEC Filing  
3/23/2017Niraj VasishtSVPSell530$1.90$1,007.00View SEC Filing  
3/23/2017Paolantonio Ernest Robert DeCFOSell170$1.90$323.00View SEC Filing  
1/30/2017Niraj VasishtInsiderSell6,905$1.91$13,188.55View SEC Filing  
12/1/2016Samuel P. Sears, Jr.DirectorSell12,000$1.67$20,040.00View SEC Filing  
11/23/2016Barry I FeinbergDirectorBuy2,000$1.67$3,340.00View SEC Filing  
11/17/2016Barry I FeinbergDirectorBuy3,000$1.87$5,610.00View SEC Filing  
9/23/2016Francis E Odonnell JrDirectorSell100,000$2.57$257,000.00View SEC Filing  
9/23/2016Niraj VasishtInsiderSell47,000$2.43$114,210.00View SEC Filing  
9/22/2016Paolantonio Ernest Robert DeCFOSell14,800$2.44$36,112.00View SEC Filing  
8/25/2016Barry I FeinbergDirectorBuy2,500$2.55$6,375.00View SEC Filing  
8/11/2016William B StoneDirectorSell16,000$2.57$41,120.00View SEC Filing  
3/21/2016Charles BramlageDirectorBuy8,850$2.82$24,957.00View SEC Filing  
3/18/2016Barry I FeinbergDirectorBuy10,000$2.74$27,400.00View SEC Filing  
3/18/2016Niraj VasishtCTOBuy1,000$2.80$2,800.00View SEC Filing  
3/17/2016Paolantonio Ernest Robert DeCFOBuy4,000$2.60$10,400.00View SEC Filing  
11/24/2015Francis E Odonnell JrDirectorSell50,000$6.01$300,500.00View SEC Filing  
11/13/2015Thomas D'alonzoDirectorBuy4,528$5.52$24,994.56View SEC Filing  
9/3/2015Francis E Odonnell JrDirectorSell20,000$6.43$128,600.00View SEC Filing  
8/26/2015Paolantonio Ernest Robert DeCFOBuy1,650$6.20$10,230.00View SEC Filing  
8/13/2015William B StoneDirectorSell11,500$7.01$80,615.00View SEC Filing  
6/16/2015Francis E Odonnell JrDirectorSell21,597$8.03$173,423.91View SEC Filing  
6/16/2015Mark A SirgoCEOSell4,187$7.97$33,370.39View SEC Filing  
5/26/2015Barry I FeinbergDirectorBuy2,000$7.84$15,680.00View SEC Filing  
5/14/2015Barry I FeinbergDirectorBuy2,000$8.54$17,080.00View SEC Filing  
5/13/2015Thomas D'alonzoDirectorBuy6,226$8.07$50,243.82View SEC Filing  
12/26/2014Francis E Odonnell JrDirectorSell70,000$12.00$840,000.00View SEC Filing  
12/15/2014Mark A SirgoCEOBuy2,500$12.23$30,575.00View SEC Filing  
12/10/2014Samuel P Sears JrDirectorSell7,853$15.03$118,030.59View SEC Filing  
11/12/2014William B StoneDirectorSell14,000$16.11$225,540.00View SEC Filing  
9/4/2014Barry I FeinbergDirectorBuy1,000$15.18$15,180.00View SEC Filing  
9/4/2014Mark A SirgoCEOBuy2,000$15.04$30,080.00View SEC Filing  
8/27/2014Andrew L FinnEVPSell90,000$15.00$1,350,000.00View SEC Filing  
8/22/2014Charles BramlageDirectorBuy1,800$13.85$24,930.00View SEC Filing  
6/25/2014Paolantonio Ernest Robert DeCFOBuy1,250$12.13$15,162.50View SEC Filing  
6/12/2014Samuel P Sears JrDirectorSell5,000$12.33$61,650.00View SEC Filing  
6/11/2014Francis E Odonnell JrDirectorSell125,000$11.04$1,380,000.00View SEC Filing  
3/26/2014Francis Odonnell, Jr.DirectorSell50,000$8.04$402,000.00View SEC Filing  
3/20/2014Samuel Sears, Jr.DirectorSell4,000$9.00$36,000.00View SEC Filing  
3/11/2014Andrew FinnEVPSell80,000$9.99$799,200.00View SEC Filing  
3/11/2014William StoneDirectorSell35,000$10.00$350,000.00View SEC Filing  
2/20/2014Andrew FinnEVPSell18,737$8.84$165,635.08View SEC Filing  
2/20/2014Francis Odonnell, Jr.DirectorSell70,000$8.92$624,400.00View SEC Filing  
2/20/2014Mark SirgoCEOSell42,000$8.92$374,640.00View SEC Filing  
1/24/2014Andrew FinnEVPSell143,679$9.03$1,297,421.37View SEC Filing  
1/24/2014James McnultySVPSell89,223$8.73$778,916.79View SEC Filing  
1/24/2014John SheaDirectorSell130,000$8.78$1,141,400.00View SEC Filing  
1/24/2014Mark SirgoCEOSell116,253$9.01$1,047,439.53View SEC Filing  
11/18/2013Mark SirgoCEOBuy2,337$4.29$10,025.73View SEC Filing  
9/19/2013Francis Odonnell, Jr.DirectorSell95,000$5.36$509,200.00View SEC Filing  
9/11/2013Samuel P Sears JrDirectorSell2,000$5.37$10,740.00View SEC Filing  
9/9/2013Samuel P Sears JrDirectorSell7,500$5.05$37,875.00View SEC Filing  
8/26/2013Andrew FinnEVPBuy5,000$4.58$22,900.00View SEC Filing  
8/16/2013Mark SirgoCEOBuy5,100$4.43$22,593.00View SEC Filing  
8/15/2013William StoneDirectorSell6,825$4.44$30,303.00View SEC Filing  
8/14/2013James McnultyCFOBuy5,000$4.50$22,500.00View SEC Filing  
6/21/2013Mark A SirgoCEOBuy3,400$4.30$14,620.00View SEC Filing  
6/20/2013Francis E Odonnell JrDirectorSell72,689$4.36$316,924.04View SEC Filing  
6/5/2013Samuel P Sears JrDirectorSell5,000$4.42$22,100.00View SEC Filing  
12/21/2012Andrew L FinnEVPBuy3,000$3.85$11,550.00View SEC Filing  
12/21/2012Mark A SirgoCEOBuy4,975$4.02$19,999.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioDelivery Sciences International (NASDAQ BDSI) News Headlines

Source:
DateHeadline
Adamis Pharmaceuticals (ADMP) versus BioDelivery Sciences International (BDSI) Critical AnalysisAdamis Pharmaceuticals (ADMP) versus BioDelivery Sciences International (BDSI) Critical Analysis
www.americanbankingnews.com - December 11 at 1:26 AM
-$0.23 EPS Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter-$0.23 EPS Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter
www.americanbankingnews.com - December 4 at 3:14 PM
Financial Comparison: BioDelivery Sciences International (BDSI) and Patheon (PTHN)Financial Comparison: BioDelivery Sciences International (BDSI) and Patheon (PTHN)
www.americanbankingnews.com - December 4 at 9:10 AM
BioDelivery Sciences International, Inc. (BDSI) Receives Consensus Rating of "Buy" from BrokeragesBioDelivery Sciences International, Inc. (BDSI) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 4 at 8:44 AM
BDSI CEO on big formulary addBDSI CEO on big formulary add
www.bizjournals.com - November 30 at 3:16 PM
Comparing SciClone Pharmaceuticals (SCLN) & BioDelivery Sciences International (BDSI)Comparing SciClone Pharmaceuticals (SCLN) & BioDelivery Sciences International (BDSI)
www.americanbankingnews.com - November 30 at 3:12 AM
BRIEF-BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To FormularyBRIEF-BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To Formulary
www.reuters.com - November 27 at 5:48 PM
BioDelivery Sciences Announces Ohio Workers Compensation Adding BELBUCA and BUNAVAIL to FormularyBioDelivery Sciences Announces Ohio Workers Compensation Adding BELBUCA and BUNAVAIL to Formulary
finance.yahoo.com - November 27 at 5:48 PM
BioDelivery Sciences International, Inc. (BDSI) PT Set at $5.00 by HC WainwrightBioDelivery Sciences International, Inc. (BDSI) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - November 27 at 1:56 PM
Roth Capital Analysts Give BioDelivery Sciences International, Inc. (BDSI) a $5.00 Price TargetRoth Capital Analysts Give BioDelivery Sciences International, Inc. (BDSI) a $5.00 Price Target
www.americanbankingnews.com - November 25 at 5:28 PM
BioDelivery Sciences International, Inc. (BDSI) Expected to Post Quarterly Sales of $9.80 MillionBioDelivery Sciences International, Inc. (BDSI) Expected to Post Quarterly Sales of $9.80 Million
www.americanbankingnews.com - November 18 at 9:00 AM
BioDelivery Sciences to Present at the 29th Annual Piper Jaffray ... - PR Newswire (press release)BioDelivery Sciences to Present at the 29th Annual Piper Jaffray ... - PR Newswire (press release)
www.prnewswire.com - November 16 at 11:52 AM
BioDelivery Sciences to Present at the 29th Annual Piper Jaffray ConferenceBioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference
finance.yahoo.com - November 16 at 11:52 AM
Zacks: Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) Will Announce Earnings of -$0.23 Per ShareZacks: Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - November 16 at 3:10 AM
Cantor Fitzgerald Analysts Lower Earnings Estimates for BioDelivery Sciences International, Inc. (BDSI)Cantor Fitzgerald Analysts Lower Earnings Estimates for BioDelivery Sciences International, Inc. (BDSI)
www.americanbankingnews.com - November 15 at 1:40 PM
BioDelivery Sciences International, Inc. Forecasted to Earn FY2017 Earnings of $0.15 Per Share (BDSI)BioDelivery Sciences International, Inc. Forecasted to Earn FY2017 Earnings of $0.15 Per Share (BDSI)
www.americanbankingnews.com - November 14 at 9:04 AM
BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update - PR Newswire (press release)BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update - PR Newswire (press release)
www.prnewswire.com - November 10 at 1:09 PM
BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates - NasdaqBioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates - Nasdaq
www.nasdaq.com - November 10 at 1:09 PM
Edited Transcript of BDSI earnings conference call or presentation 9-Nov-17 9:30pm GMTEdited Transcript of BDSI earnings conference call or presentation 9-Nov-17 9:30pm GMT
finance.yahoo.com - November 10 at 1:09 PM
BioDelivery Sciences International, Inc. (BDSI) Announces  Earnings ResultsBioDelivery Sciences International, Inc. (BDSI) Announces Earnings Results
www.americanbankingnews.com - November 10 at 12:51 PM
Investor Network: BioDelivery Sciences International, Inc. to Host Earnings CallInvestor Network: BioDelivery Sciences International, Inc. to Host Earnings Call
www.finanznachrichten.de - November 9 at 5:34 PM
BioDelivery Sciences International, Inc. 2017 Q3 - Results - Earnings Call SlidesBioDelivery Sciences International, Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 9 at 5:34 PM
BioDelivery Sciences International, Inc. to Host Earnings CallBioDelivery Sciences International, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 5:34 PM
Is BioDelivery Sciences International Inc’s (BDSI) Balance Sheet Strong Enough To Weather A Storm?Is BioDelivery Sciences International Inc’s (BDSI) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 9 at 5:34 PM
BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateBioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 5:34 PM
BioDelivery reports 3Q lossBioDelivery reports 3Q loss
finance.yahoo.com - November 9 at 5:33 PM
BioDelivery Sciences International, Inc. (BDSI) Given Average Recommendation of "Buy" by BrokeragesBioDelivery Sciences International, Inc. (BDSI) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 9 at 8:30 AM
BioDelivery (BDSI) to Report Q3 Earnings: Whats in Store?BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?
www.zacks.com - November 7 at 11:52 PM
BioDelivery (BDSI) to Report Q3 Earnings: Whats in Store? - NasdaqBioDelivery (BDSI) to Report Q3 Earnings: What's in Store? - Nasdaq
www.nasdaq.com - November 7 at 6:52 PM
BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?
finance.yahoo.com - November 7 at 6:51 PM
Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences ... - PR Newswire (press release)Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences ... - PR Newswire (press release)
www.prnewswire.com - November 4 at 3:05 AM
Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences International, Inc. (NASDAQ:BDSI)Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
finance.yahoo.com - November 3 at 10:04 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by BioDelivery Sciences International, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by BioDelivery Sciences International, Inc.
finance.yahoo.com - November 2 at 5:05 PM
BioDelivery Sciences International, Inc. (BDSI) Scheduled to Post Quarterly Earnings on TuesdayBioDelivery Sciences International, Inc. (BDSI) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 7:44 AM
BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2017 Financial Results on ... - PR Newswire (press release)BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2017 Financial Results on ... - PR Newswire (press release)
www.prnewswire.com - October 30 at 10:53 PM
BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2017 Financial Results on November 9BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2017 Financial Results on November 9
finance.yahoo.com - October 30 at 5:32 PM
ETFs with exposure to BioDelivery Sciences International, Inc. : October 30, 2017ETFs with exposure to BioDelivery Sciences International, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 5:32 PM
Piper Jaffray Companies Reiterates Buy Rating for BioDelivery Sciences International, Inc. (BDSI)Piper Jaffray Companies Reiterates Buy Rating for BioDelivery Sciences International, Inc. (BDSI)
www.americanbankingnews.com - October 22 at 6:20 AM
ETFs with exposure to BioDelivery Sciences International, Inc. : October 20, 2017ETFs with exposure to BioDelivery Sciences International, Inc. : October 20, 2017
finance.yahoo.com - October 20 at 6:13 PM
BioDelivery Sciences International, Inc. (BDSI) Receives Average Rating of "Buy" from AnalystsBioDelivery Sciences International, Inc. (BDSI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 15 at 9:00 AM
Roth Capital Reiterates $5.00 Price Target for BioDelivery Sciences International, Inc. (BDSI)Roth Capital Reiterates $5.00 Price Target for BioDelivery Sciences International, Inc. (BDSI)
www.americanbankingnews.com - October 14 at 11:42 AM
BioDelivery Sciences International, Inc. (BDSI) Sees Significant Drop in Short InterestBioDelivery Sciences International, Inc. (BDSI) Sees Significant Drop in Short Interest
www.americanbankingnews.com - October 14 at 2:04 AM
Head to Head Comparison: BioDelivery Sciences International (BDSI) versus Its CompetitorsHead to Head Comparison: BioDelivery Sciences International (BDSI) versus Its Competitors
www.americanbankingnews.com - October 14 at 12:46 AM
HC Wainwright Analysts Give BioDelivery Sciences International, Inc. (BDSI) a $5.00 Price TargetHC Wainwright Analysts Give BioDelivery Sciences International, Inc. (BDSI) a $5.00 Price Target
www.americanbankingnews.com - October 13 at 9:36 AM
BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva - PR Newswire (press release)BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva - PR Newswire (press release)
www.prnewswire.com - October 13 at 3:21 AM
Cantor Fitzgerald Analysts Give BioDelivery Sciences International, Inc. (BDSI) a $5.00 Price TargetCantor Fitzgerald Analysts Give BioDelivery Sciences International, Inc. (BDSI) a $5.00 Price Target
www.americanbankingnews.com - October 12 at 11:52 PM
BRIEF-BioDelivery sciences announces patent litigation settlement agreement with TevaBRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva
www.reuters.com - October 12 at 10:18 PM
BioDelivery Sciences Announces Patent Litigation Settlement Agreement with TevaBioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva
finance.yahoo.com - October 12 at 5:15 PM
BDSI settles patent litigation with generic giant TevaBDSI settles patent litigation with generic giant Teva
finance.yahoo.com - October 12 at 5:15 PM
ETFs with exposure to BioDelivery Sciences International, Inc. : October 9, 2017ETFs with exposure to BioDelivery Sciences International, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 5:20 PM

SEC Filings

BioDelivery Sciences International (NASDAQ:BDSI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioDelivery Sciences International (NASDAQ:BDSI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioDelivery Sciences International (NASDAQ BDSI) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.